T-DM1 Slows Breast Cancer, with Fewer Side Effects
By Anette Breindl
Wednesday, June 6, 2012
CHICAGO Roche AG subsidiary Genentech Inc. and partner ImmunoGen Inc. had what looks to be another winner at Sunday's plenary session of the American Society of Clinical Oncology (ASCO) annual meeting.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.